Presentation
16 March 2023 Wide-field optical redox imaging with leading-edge detection for assessment of patient-derived cancer organoids (Conference Presentation)
Author Affiliations +
Abstract
Patient-derived cancer organoids (PDCOs) are valuable for patient management and drug development. Label-free widefield optical redox ratio (WF-ORR) imaging measures organoid-level treatment response using the autofluorescence intensity of the metabolic co-enzymes NAD(P)H and FAD. We have developed WF-ORR imaging and analysis tools to maximize the accessibility, speed, sensitivity, and reproducibility of drug response measurements in PDCOs. These tools include leading-edge segmentation methods that isolate ORR changes within the proliferating zone of PDCOs, and single organoid tracking that reduces variability within drug screens. Overall, this approach enables rapid, sensitive, and reproducible measurements of treatment response and heterogeneity in PDCOs.
Conference Presentation
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Amani A. Gillette, Shirsa Udgata, Lexie Schmitz, Dustin Deming, and Melissa C. Skala "Wide-field optical redox imaging with leading-edge detection for assessment of patient-derived cancer organoids (Conference Presentation)", Proc. SPIE PC12391, Label-free Biomedical Imaging and Sensing (LBIS) 2023, PC1239107 (16 March 2023); https://doi.org/10.1117/12.2650100
Advertisement
Advertisement
KEYWORDS
Cancer

Optical imaging

Clinical trials

Drug development

3D image processing

3D metrology

Image segmentation

Back to Top